ライフサイエンスコーパス: cerebrovascular accident

1 -617 group and one in the ARPI change group (cerebrovascular accident).

2 uscitated cardiac arrest; and 1 died after a cerebrovascular accident.

3 nt was withdrawn from the study because of a cerebrovascular accident.

4 mic cerebrovascular accident, or hemorrhagic cerebrovascular accident.

5 tcomes were death, myocardial infarction, or cerebrovascular accident.

6 ery disease, prior myocardial infarction, or cerebrovascular accident.

7 entricular arrhythmias, current smoking, and cerebrovascular accident.

8 eased after cardiac death, or deceased after cerebrovascular accident.

9 eath of any cause, myocardial infarction, or cerebrovascular accident.

10 due to any cause, myocardial infarction, or cerebrovascular accident.

11 mg/dL, history of hypertension, or death by cerebrovascular accident.

12 the follow-up period, one mother died from a cerebrovascular accident.

13 ve Q-wave myocardial infarctions, and 6 (5%) cerebrovascular accidents.

14 ncluding thrombosis, recurrent bleeding, and cerebrovascular accidents.

15 emboli, infection, myocardial infarction and cerebrovascular accidents.

16 urologic prognosis of patients with ischemic cerebrovascular accidents.

17 nces in pneumonia, thromboembolic events, or cerebrovascular accidents.

18 increased risk for death and potentially for cerebrovascular accidents.

19 ogenesis of anatomic derangements underlying cerebrovascular accidents.

20 significant reductions in rates of confirmed cerebrovascular accidents (0%, P = .015) and mortality (

21 jor hemorrhage (1.7% vs. 2.3%; p = 0.61), or cerebrovascular accident (1.2% vs. 1.5%; p = 0.77).

22 trial fibrillation (4.2% vs 18.0%, p=0.001), cerebrovascular accident (1.7% vs 7.0%, p=0.04), and pos

23 ence interval, 1.06-1.21) and a trend toward cerebrovascular accident (10-year hazard ratio, 1.08; 95

24 rs (p < 0.001) and the highest prevalence of cerebrovascular accidents (10%, p = 0.001).

25 had the highest percentage of damage due to cerebrovascular accident (12.8%) and venous thrombosis (

26 scular disease (myocardial infarction, 5.1%; cerebrovascular accident, 2.0%) were followed for a medi

27 793 subjects died, including 279 who died of cerebrovascular accident, 217 who died of cancer, and 20

28 ardiovascular death (6.0 vs 6.0%, p=0.86) or cerebrovascular accident (3.6 vs 3.5%, p=0.31).

29 common (13% vs 8%), whereas rate of ischemic cerebrovascular accident (4% each) and venous thromboemb

30 schaemic heart disease (6.3 million deaths), cerebrovascular accidents (4.4 million deaths), lower re

31 Cerebrovascular accident (40%) was the most prevalent ca

32 c kidney or other renal diseases (51%, 44%), cerebrovascular accident (43%, 44%), and cardiovascular

33 njury (28.0%), sepsis (24.6%), shock (8.6%), cerebrovascular accident (5.2%), and venous thromboembol

34 dent: 7.7% versus 3.4%, P<0.001; hemorrhagic cerebrovascular accident: 7.2% versus 2.0%, P<0.001) tha

35 attack: 3.3% versus 1.0%, P<0.001; ischemic cerebrovascular accident: 7.7% versus 3.4%, P<0.001; hem

36 e was no significant increase in the risk of cerebrovascular accidents, acute myocardial infarction,

37 About 60% of the cerebrovascular accidents affected the right cerebral he

38 e neurologic deficit, and 5% developed a new cerebrovascular accident after dissection repair.

39 ent coronary artery bypass graft surgery, or cerebrovascular accident after PCI.

40 Cerebrovascular accidents after PCI, although rare, are

41 Cerebrovascular accidents after PCI, although rare, can

42 omplications (aHR, 0.49; 95% CI, 0.41-0.58), cerebrovascular accident (aHR, 0.60; 95% CI, 0.50-0.73),

43 ferences in death, myocardial infarction, or cerebrovascular accident among patients enrolled in the

44 ho do not undergo surgical removal, rates of cerebrovascular accident and mortality are increased.

45 donors with treated coronary artery disease, cerebrovascular accident and nonbrain, nonskin primary m

46 ) died because of an adverse event (one [7%] cerebrovascular accident and one [7%] respiratory failur

47 (CHF), abdominal aortic aneurysm (AAA), and cerebrovascular accident and tracked triglyceride, high-

48 inically evident, radiographically confirmed cerebrovascular accidents and 60-day mortality and evalu

49 Primary end points included cerebrovascular accidents and all-cause mortality in the

50 astrocytes in tissue surrounding new and old cerebrovascular accidents and brain tumours.

51 ns in cerebral blood flow (CBF), hemorrhage, cerebrovascular accidents and death.

52 DAPT patients had significantly fewer total cerebrovascular accidents and fewer total strokes compar

53 acute care hospitals, aged </= 70 years from cerebrovascular accidents and trauma.

54 tomatic fibrillation and reduces the risk of cerebrovascular accidents and ventricular tachycardia.

55 gastric ulcer perforation, sudden death, and cerebrovascular accident) and the placebo group (sudden

56 symptoms included transient ischemic attack, cerebrovascular accident, and amaurosis fugax.

57 rt (1.0% vs. 1.2%) and no difference in AAA, cerebrovascular accident, and CHF.

58 associated with increased risk of death, HF, cerebrovascular accident, and myocardial infarction (p <

59 Subjects were followed for death, HF, cerebrovascular accident, and myocardial infarction with

60 cident) and the placebo group (sudden death, cerebrovascular accident, and pneumonia), with none in t

61 coma lasting >24 hours, acute renal failure, cerebrovascular accident, and pulmonary embolism.

62 h, aortic dissection, myocardial infarction, cerebrovascular accident, and pulmonary embolism.

63 e = 2.5 mg/dL), peripheral vascular disease, cerebrovascular accident, and severe obesity (body mass

64 y mortality; nonfatal myocardial infarction, cerebrovascular accident, and stage 2 to 3 acute kidney

65 n, tachydysrythmias, myocardial infarctions, cerebrovascular accidents, and deaths.

66 bidity (such as the acute coronary syndrome, cerebrovascular accidents, and heart failure) was collec

67 omposite of death, myocardial infarction, or cerebrovascular accidents, and occurrence of the key saf

68 ore the invasion were myocardial infarction, cerebrovascular accidents, and other chronic disorders w

69 About 30% of ischemic cerebrovascular accidents are caused by proximal obstruc

70 rial fibrillation and related cardio-embolic cerebrovascular accidents are two well-defined major hea

71 cular system, causing myocardial infarction, cerebrovascular accidents, arrhythmia and heart failure.

72 hree patients (2%) in the pravastatin group (cerebrovascular accident, arteriosclerosis coronary arte

73 organs, especially from ECD and donors with cerebrovascular accident as cause of death, and to impro

74 These factors included donor age, cerebrovascular accident as the cause of death, renal in

75 ath, nonfatal myocardial infarction (MI), or cerebrovascular accident at 24 months.

76 manifest as embolic phenomena, particularly cerebrovascular accidents, bearing substantial mortality

77 I, 3.9-6.1; OR, 2.3; 95% CI, 1.7-3.2), acute cerebrovascular accident (beta coefficient, 6.6; 95% CI,

78 neurologic disorders and injuries (including cerebrovascular accidents, brain trauma, brain tumors, a

79 dial infarction, coronary revascularization, cerebrovascular accident, carotid endarterectomy, periph

80 -year-old female patient with a history of a cerebrovascular accident caused by a right pontine arter

81 Subject Headings alcohol drinking, ethanol, cerebrovascular accident, cerebrovascular disorders, and

82 nsion, a silent myocardial infarction, and a cerebrovascular accident complicated by seizures.

83 ient death from acute myocardial infarction, cerebrovascular accident, congestive heart failure, or p

84 t for total CVD-related mortality for BD and cerebrovascular accident (CVA) for mixed SMI.

85 on (AMI), congestive heart failure (CHF), or cerebrovascular accident (CVA) from 1991 to 1994.

86 Twenty patients had at least one cerebrovascular accident (CVA) in follow-up; 35 patients

87 tion (AF), use of warfarin and prevalence of cerebrovascular accident (CVA) in paced versus unpaced p

88 There was a higher prevalence of cerebrovascular accident (CVA) in patients with SEC when

89 Cerebrovascular accident (CVA) is a major complication o

90 rimary end point was the first occurrence of cerebrovascular accident (CVA) or death.

91 e rate of resolution of iBCVIs, freedom from cerebrovascular accident (CVA) or transient ischemic att

92 pAF is associated with an increased risk of cerebrovascular accident (CVA) remains uncertain.

93 th SFCT (coefficient = 5.69), and history of cerebrovascular accident (CVA) was significantly inverse

94 rative predictors of complication were prior cerebrovascular accident (CVA), chronic obstructive pulm

95 rated contralateral carotid occlusion, prior cerebrovascular accident (CVA), or SPs less than 35 mmHg

96 ding mortality, intraoperative/postoperative cerebrovascular accident (CVA), postoperative bleeding,

97 ite of death, myocardial infarction (MI), or cerebrovascular accident (CVA).

98 There is an increased risk of cerebrovascular accidents (CVA) in individuals with PHAC

99 hospitalized myocardial infarctions (MI) and cerebrovascular accidents (CVA) in patients with diabeti

100 Cerebrovascular accidents (CVA) or ischemic heart diseas

101 42 339 in-hospital deaths </= 70 years from cerebrovascular accidents (CVA) or trauma that were corr

102 ailure (CHF), coronary artery disease (CAD), cerebrovascular accidents (CVA), chronic obstructive pul

103 ailure (CHF), coronary artery disease (CAD), cerebrovascular accidents (CVA), diabetes mellitus (DM),

104 tes (T2D), cardiovascular disease (CVD), and cerebrovascular accidents (CVA).

105 oung women with UC have an increased risk of cerebrovascular accidents (CVA).

106 ce, predictors, and clinical implications of cerebrovascular accidents (CVAs) after percutaneous coro

107 ation and should be considered high-risk for cerebrovascular accidents (CVAs) in PHACES patients.

108 , to evaluate its effect on the incidence of cerebrovascular accidents (CVAs).

109 tive heart failure, coronary artery disease, cerebrovascular accidents, diabetes mellitus, and end-st

110 vational study included adults with ischemic cerebrovascular accidents due to obstruction of the ante

111 in the management of patients with ischemic cerebrovascular accidents due to proximal occlusion.

112 ean age, 82 y; 41 (75%) women] with ischemic cerebrovascular accidents due to proximal occlusion.

113 neurologic prognosis after anterior ischemic cerebrovascular accidents due to proximal vascular obstr

114 dial Infarction, ventricular arrhythmia, and cerebrovascular accident during follow-up, albeit with d

115 dial Infarction, ventricular arrhythmia, and cerebrovascular accident during follow-up.

116 ardial infarction, congestive heart failure, cerebrovascular accident, gastrointestinal tract hemorrh

117 eline variables (death/myocardial infarction/cerebrovascular accident: hazard ratio: 1.11, 99% confid

118 sease (a composite of myocardial infarction, cerebrovascular accident, heart failure, and peripheral

119 complication (HR, 5.37 [95% CI, 4.65-6.20]), cerebrovascular accident (HR, 3.82 [95% CI, 2.94-4.96]),

120 l infarction (HR, 6.3; 95% CI, 2.9 to 13.9), cerebrovascular accident (HR, 6.0; 95% CI, 2.6 to 14.1),

121 >50 years, female sex, death attributable to cerebrovascular accident, hypertension, diabetes mellitu

122 ), and ischemic stroke (CV death/MI/ischemic cerebrovascular accident [iCVA]).

123 patients, myocardial infarction in 9 (0.4%), cerebrovascular accident in 38 (1.5%), and acute kidney

124 boli despite prophylaxis and an unrecognized cerebrovascular accident in one patient each.

125 phropathy in one patient, and death due to a cerebrovascular accident in one patient.

126 l cell carcinoma in the ozanezumab group and cerebrovascular accident in the placebo group).

127 Major bleeding events occurred in 33% and cerebrovascular accidents in 14%.

128 igate the role of ANP in the pathogenesis of cerebrovascular accidents in humans.

129 may represent an independent risk factor for cerebrovascular accidents in humans.

130 could underlie the unfavorable prognosis of cerebrovascular accidents in sleep apnea patients.

131 matics in a female patient recovering from a cerebrovascular accident involving anterior regions of t

132 nt of interest was major adverse cardiac and cerebrovascular accident (MACCE) (death, myocardial infa

133 as deep vein thrombosis, pulmonary embolism, cerebrovascular accident, myocardial injury, acute kidne

134 Acute organ injuries such as acute cerebrovascular accidents, myocardial infarction, acute

135 2 years and reported the outcome measures of cerebrovascular accidents, myocardial infarctions, arter

136 dical cause: cardiovascular disease (n = 2), cerebrovascular accident (n = 1), metabolic collapse and

137 Reported AEs were thromboembolic cerebrovascular accident (n = 39), acute myocardial infa

138 Indications for placement were cerebrovascular accident (n = 80), failure to thrive (n

139 the placebo group, these adverse events were cerebrovascular accident (n=1), multiple organ dysfuncti

140 tinal haemorrhage, hepatorenal syndrome, and cerebrovascular accident [n=1 each]).

141 context of progressive disease, sepsis, and cerebrovascular accident; none were considered by the in

142 Cerebrovascular accident occurred in 0.3%, and transfusi

143 ped hemodynamic compromise and no documented cerebrovascular accident occurred within one month after

144 Cerebrovascular accident occurs in a low proportion of i

145 Vision loss and cerebrovascular accidents often complicate giant cell ar

146 n-hospital mortality, myocardial infarction, cerebrovascular accident or transient ischemic attack, r

147 1) or having a residual deficit from a prior cerebrovascular accident (OR, 1.17; 95% CI, 1.11-1.22; P

148 mg ranibizumab yielded an increased risk for cerebrovascular accidents (OR, 2.33; 95% CI, 1.04-5.22;

149 ns for myocardial infarction, heart failure, cerebrovascular accident, or angina after the index angi

150 omposite end point of myocardial infarction, cerebrovascular accident, or cardiovascular death during

151 fined as transient ischemic attack, ischemic cerebrovascular accident, or hemorrhagic cerebrovascular

152 story of myocardial infarction, a history of cerebrovascular accident, or history of alcohol abuse.

153 f cardiac death, myocardial infarction (MI), cerebrovascular accident, or re-vascularization occurred

154 st, heart failure, intracerebral hemorrhage, cerebrovascular accident, or reinfarction.

155 idual risks of death, myocardial infarction, cerebrovascular accident, or stent thrombosis did not di

156 ent (myocardial infarction, angina pectoris, cerebrovascular accidents, or major coronary surgery).

157 riates were defined: cardiovascular disease, cerebrovascular accident, peripheral vascular disease, d

158 irculatory collapse, wound infection, ileus, cerebrovascular accident [possibly treatment related], a

159 mia, coronary stenosis, coronary restenosis, cerebrovascular accident, randomized controlled trial, c

160 ing 30-day mortality, myocardial infarction, cerebrovascular accident, rebleeding, pneumonia, or thro

161 come was a composite of all-cause mortality, cerebrovascular accident, reinfarction, or unplanned tar

162 .610; 95% confidence interval, 0.440-0.847), cerebrovascular accidents (relative risk, 0.840; 95% con

163 Ischemic and hemorrhagic cerebrovascular accidents remain common among patients w

164 Rates of cerebrovascular accident, return to cardiopulmonary bypa

165 Cerebrovascular accident risk in group 2 at 1 and 5 year

166 > or =6 months) transient ischemic attack or cerebrovascular accident, smoking history, and creatinin

167 iac failure, peritonitis, pneumonia, sepsis, cerebrovascular accident, suicide, pneumothorax, and pul

168 r composite of death, myocardial infarction, cerebrovascular accident, target vessel revascularizatio

169 oped adverse neurological events, defined as cerebrovascular accident, transient ischemic attack (TIA

170 The composite primary end point was cerebrovascular accident, transient ischemic attack, and

171 idences of death or readmission for embolic (cerebrovascular accident, transient ischemic attack, and

172 associated with all-cause mortality, but not cerebrovascular accident/transient ischemic attack, LVAD

173 Cerebrovascular accidents/transient ischemic attacks occ

174 ed arterial events (myocardial infarction or cerebrovascular accident), venous events (deep vein thro

175 Although cerebrovascular accident was associated with an increase

176 The incidence of cerebrovascular accident was not significantly reduced b

177 monary vein isolation or after cardioembolic cerebrovascular accident was performed using standard ap

178 ertension, diabetes mellitus, and history of cerebrovascular accident, were similar between groups (2

179 a come almost exclusively from patients with cerebrovascular accidents where brain damage extends int

180 ine group (the most common adverse event was cerebrovascular accident, which occurred in 3 participan

181 onfatal myocardial infarctions, and nonfatal cerebrovascular accidents, which are possible effects fr

182 The main outcome measure was cerebrovascular accident within 12 months of diagnosis.

183 ty analyses revealed that the annual risk of cerebrovascular accident would have to be at least 1.5%